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128 Poster Session IIThe detection of naturally occurring T cells responding to pro-
teins overexpressed in myeloid leukemia suggests that vaccines
could boost the immune response to leukemia and achieve disease
control. Human neutrophil elastase (HNE) is a myeloid-restricted
protein highly expressed in myeloid leukemia cells. HNE protein
can induce both CD41 and CD81 T cell responses in healthy in-
dividuals including HLA-A*0201 negative individuals. To develop
HNE protein vaccine, and to identify major histocompatibility
complex (MHC) class II restricted or HLA-A*0201 negative
MHC class I restricted epitopes in HNE, we stimulated peripherial
blood mononuclear cells (PBMC) from 6 myeloid leukemia pre-
transplant patients with purified full length HNE protein. HNE
protein induced a response in CD41 and CD81T cells from 4 pa-
tients with acute myeloid leukemia (AML), as measured by IFN-g
protein expression in flow cytometric assay. However, no response
was detected in CD41 and CD81T cells from 2 pre-transplant pa-
tients with chronic myeloid leukemia (CML). Responses of CD41
and CD81 T cells to HNE protein stimulation were enhanced by
HNE expressing antigen-presenting T cells (T-APC), as measured
by flow cytometric assay. HNE protein induced significant IFN-g
expression in CD41 and CD81 T cells at 540X and 10X above
background in an (HLA-A11, 31) AML patient (patient #1), and
at 6X and 3.5X above background in an (HLA-A*0205, 03*) AML
patient (patient #2), as measured by quantitative Real-Time RT-
PCR assay (QRT-PCR). HNE protein also induced significant
IL-2 production in CD41 and CD81 T cells at 7.7X and 6.1X
above background in patient #1. Finally, we showed by QRT-
PCR that the T cell responses to HNE protein stimulation were
associated with the levels of HNE gene transcripts in the PBMC.
Further inverstigation of the correlation betweenHNEprotein spe-
cific CD41 and CD81T-cell responses and HNE gene transcripts
in consecutive samples obtained pre- and post-SCT may define an
ideal timewindow to vaccinate post-SCTpatients withmyeloid leu-
kemias. We found that full-length HNE protein stimulated both
CD41 and CD81 T cell responses in HLA-A*0201 negative pa-
tients with AML in the first three months following SCT. These re-
sults provide the rationale for using HNE protein to vaccinate
patients with myeloid leukemias after SCT to improve graft-ver-
sus-leukemia effects.349
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Adoptive transfer of polyclonal CD41CD251 regulatory T cells
(nTregs) can tolerize transplantation alloresponses and prevent le-
thal acute graft-versus-host disease (GVHD) in mice. However iso-
lation of human CD41CD251 nTregs for adoptive
immunotherapy in sufficient numbers is cumbersome and prone
to contamination with non-regulatory, alloreactive CD251 T-
cells. Incubation of ethylenecarbodiimide (ECDI)-coupled antigen
presenting cells (APC) with naı¨ve T-cells and antigen has been
shown to induce tolerance in various experimental models.
We have therefore hypothesized that ECDI-coupled APC would
be able to tolerize alloreactive naı¨ve human CD41 T-cells from
HLA-incompatible human donors, and have tested whether this
would induce a Treg-like CD41 population (ECDI-Tregs). We
further investigated whether these cells could be expanded ex vivo
without loss of their regulatory capacity.
After 5 days of culture, ECDI-Tregs were as potent as freshly iso-
lated nTregs to suppress proliferation of effector T-cells in a mixed
lymphocyte reaction with allo-APC from the original APC donor
and they maintained high expression of CD62L and CD27 as well
as low CD127 expression. Foxp3 mRNA levels and Foxp3 protein
expression was significantly increased in ECDI-Tregs compared
to cells culturedwith untreated APC or freshly isolatedCD41 cells,
indicating either de novo induction or preferential expansion of
Tregs. ECDI treatment of APC resulted in increased apoptosis
and downregulation of costimulatory molecules CD40, CD80 and
CD86 while HLA-DR expression remained unchanged compared
to untreated cells. This might implicate T-cell receptor - MHC in-teraction without proper costimulation as a possible mechanism for
ECDI-Tregs induction. Addition of IL-2 and rapamycin and
weekly re-stimulation with untreated allo-APC led to exponential
expansion of ECDI-Tregs with increasing foxp3 levels and without
loss of their suppressive activity after 28 days.
These findings provide a proof of principle that ECDI-coupled
allo-APC can induce a potent regulatory T-cell population that
can be expanded ex vivo. These inducible Tregs suggests a novel ap-
proach to enhance the feasibility and effectiveness of inducing toler-
ance by Tregs as an adoptive immunotherapy in transplantation.350
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Acute graft versus host disease (GVHD) is the major complica-
tion after allogeneic (allo) stem cell transplantation (SCT) involving
injury to host tissues by both inflammatory cytokines and donor-de-
rived cellular effectors. Macrophage migration inhibitory factor
(MIF) is produced by various cell types and has a broad range of
proinflammatory properties. We tested, whether MIF contributes
to GVHD by using a well established murine model. Lethally
(1300 cGy) irradiated B6D2F1 (H-2bxd) mice received SCT either
from syngeneic (syn) (B6D2F1) or allo (B6; H-2b) donors. One half
of animals after either syn or allo SCT were treated with polyclonal
antibodies against mouse MIF from day 0 until day 14, whereas the
other halves of syn and allo recipients received control IgG. GVHD
severity was assessed after SCTby survival and a clinical scoring sys-
tem assessing weight changes, fur texture, skin integrity, mobility
and posture. Syn recipients stayed clinically well and all animals sur-
vived regardless their treatment with control or anti-MIF. Animals
receiving allo-SCT plus control IgG developed significant aGVHD
and high mortality. By contrast, in allo anti-MIF treated recipients,
GVHD scores (day 21: 4.4 6 0.4 vs. 5.7 6 0.5) and weight loss
(24.6% vs. 45.4%) were reduced, and survival significantly im-
proved (p\0.05). In addition, target organ injury to the gut (histo-
pathology score: 4.3 6 0.7 vs. 8.0 6 2.6) as well as serum IFNg
(4397 6 995 vs. 6070 6 525 pg/ml) and TNFa (113.9 6 12.7 vs.
159.2 6 22.5 pg/ml) levels of anti-MIF treated allo recipients
were decreased by day 7 when compared to controls. Alloantigen-
specific T cell activation in vitro was significantly suppressed in
the presence of anti-MIF, as determined by a reduction in T cell
proliferation, IFNg and TNFa secretion.
We next challenged syn and allo recipients with P815 lympho-
blast-like mastocytoma cells (H-2d) at the time of transplantation
to asses the effect of anti-MIF on graft versus leukemia (GVL) re-
sponses. Significant P815 cell infiltration was seen after syn SCT
as demonstrated by FACS analysis of the spleens (67.2% infiltra-
tion) and by histopathology of the liver between day 14 and day
21 after SCT. In contrast, P815 cells were significantly cleared in
allo recipients treated with either control or anti-MIF (0.81% and
12.1% infiltration).
In summary, our data show an important role for MIF in GVHD
pathophysiology and suggest MIF as a promising target in reducing
GVHD without the loss of GVL.351
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